UroGen Pharma Ltd. (NASDAQ:URGN) is one of the best small-cap biotech stocks to buy according to analysts. UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs On November 6, 2025, UroGen Pharma Ltd. (NASDAQ:URGN) reported its Q3 2025 results, highlighting strong growth in demand alongside its steady commercial expansion. Furthermore, preliminary October figures indicated that demand revenue more than doubled compared to the previous three months. This growth reflects the ...